Evista (Raloxifene) was approved for Breast cancer treatment by Food and Drug administration for some post-menopausal women. After Tamoxifen, Evista is the second drug approved for breast cancer treatment. Evista should not be prescribed for all women because of serious side effects.
Evista is advised for treatment in two groups of women to lower the risk of invasive breast cancer.
1. Postmenopausal women with osteoporosis.
2. Postmenopausal women at high risk for invasive breast cancer.
Tamoxifen is the best drug for premenopausal women who have a breast cancer risk while Raloxifene is preferred for postmenopausal women. Evista does not treat existing breast cancer.
Oncologist should weigh potential benefits and risks before prescribing Evista to postmenopausal women who are at high risk for invasive breast cancer.
